Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 22, 20 December 2023
Open
Access | Article
Advantages and disadvantages of glycomacropeptide therapy for phenylketonuria compared with traditional diet therapy
* Author to whom correspondence should be addressed.
Abstract
Phenylketonuria is an autosomal recessive disease for which there is no cure, which has a lasting adverse impact on patients' lives. At present, only two treatment methods have been widely used in clinical practice, one is traditional long-term low protein diet therapy, the other is glycomacropeptide therapy. However, the two methods have defects such as poor food palatability, poor patient compliance, and unclear immunity. Therefore, it is particularly important to explore the potential advantages and complementary advantages of the two widely used methods to improve patients' lives. This paper mainly applies the research method of literature review to explore and analyze the advantages and disadvantages of traditional diet therapy and glycomacropeptide therapy. The conclusion of this study is that in order to benefit the existing PKU patients to a greater extent and improve their quality of life and treatment effect, traditional diet therapy should be given priority, supplemented by glycomacropeptide therapy, and the two dietary plans should be implemented in parallel, so as to achieve better results. In addition, do not use the two treatment schemes in isolation.
Keywords
phenylketonuria, glycomacropeptide, phenylketonuria therapy, low protein diet
References
1. NIU Rui-qing，FENG Wen-hua. Research progress of phenylketonuria and its releveant treatment. Chinese Journal of NewDrugs 2018,27(2): 154.
2. NIU Rui-qing，FENG Wen-hua. Research progress of phenylketonuria and its releveant treatment. Chinese Journal of NewDrugs 2018,27(2): 154.
3. Zhou Zhongshu, Li Peng. Progress in the diagnosis and treatment of phenylketonuria. Beijing Medical Science, 2014, Volume 36, Issue 4:250.
4. Lu Ying, Meng Meng. Medical and nutritional treatment of phenylketonuria. 1994-2022 China Academic Journal Electronic Publishing House: 78.
5. Liu Zhidong, Wang Yinyu, Guo Benheng. Development of Research on Caseinoglycomaropeptide. Nat Prod Res Dev 2010,22:709.
6. Christineh N. Sarkissian et al.(1999). different approach to treatment of phenylketonuria: Phenylalanine degradation with recombinant phenylalanine ammonia lyase. PANS. Vol. 96 | No. 5
7. Diao Ruili, Yan Yali. Study on Preparation Technology of Casein Glycomacropeptide and the Exploitation of Special Food for Phenylketonuria Patients. 1994-2022 China Academic Journal Electronic Publishing House: 2-5.
8. Diao Ruili, Yan Yali. Study on Preparation Technology of Casein Glycomacropeptide and the Exploitation of Special Food for Phenylketonuria Patients. 1994-2022 China Academic Journal Electronic Publishing House: 5.
9. LU Chenhui , HE Yongxi, WEI Haodong , FENG Yongwei, GAO Hui, SHI Xueli, ZHANG Yi. Development and Application Progress of Food for Special Medical Purpose for Phenylketonuria. Science and Technology of Food Industry: 2.
10. Huang Wenliang. Value of low phenylalanine diet therapy in the treatment of phenylketonuria in children. CHINA JOURNAL OF PHARMACEUTICAL ECONOMICS. Issue 12,2016:122-123.
11. Hildegard P，Hans-Joachim B .Nutrition，physical growth，and bone density in treated Phenylketonuria[J] .European Journal of Pediatrics，2000，159（S2）:S129-S135.
12. Zamani R，Karimi-Shahanjarini A，Tapak L，et al.Improving Phenylalanine and micronutrients status of children with Phenylketonuria:a pilot randomized study[J]. Orphanet Journal of Rare Diseases，2021，16（1）:1-10.
13. Huemer M，Födinger M，Bodamer O A，et al. Total homocysteine，B-vitamins and genetic polymorphisms in patients with classical Phenylketonuria[J]. Molecular genetics and metabolism，2008，94（1）:46-51.
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 3rd International Conference on Biological Engineering and Medical Science
- ISBN (Print)
- 978-1-83558-217-6
- ISBN (Online)
- 978-1-83558-218-3
- Published Date
- 20 December 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/22/20230943
- Copyright
- 20 December 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited